Mifepristone (RU486): Progesterone Antagonist in Cancer & Reproduction

Executive Summary: Mifepristone (RU486) is a highly selective progesterone receptor antagonist with demonstrated efficacy in inhibiting ovarian, breast, prostate, and gastric cancer cell proliferation, and in reducing uterine fibroid size in animal models (APExBIO product information). It modulates reproductive functions by blocking progesterone signaling and suppresses the acrosome reaction in human sperm in a dose-dependent manner. The compound displays high solubility in DMSO and ethanol, with recommended storage at -20°C. Recent protocols leverage Mifepristone for both in vitro and in vivo studies at concentrations ranging from 0.04 to 40 μM and 0.5–1.0 mg/day, respectively. This article details the molecular mechanism, application benchmarks, and workflow integration strategies for research professionals.

Biological Rationale

Mifepristone’s primary biological function is antagonism of the progesterone receptor (PR), a nuclear hormone receptor essential for reproductive tissue maintenance, menstrual cycle regulation, and pregnancy. PR signaling also contributes to the survival and proliferation of hormone-dependent tumor cells, including ovarian and breast cancers. By inhibiting PR, Mifepristone disrupts critical downstream transcriptional programs, resulting in suppressed cell growth and altered tissue responses (see detailed mechanistic review). Recent studies have also highlighted the relevance of PR-p53-HO1-GPX4 axis in mediating ferroptosis and tumor suppression, further broadening Mifepristone’s research utility.

Mechanism of Action of Mifepristone (RU486)

Mifepristone (RU486) acts as a competitive antagonist of the progesterone receptor, blocking progesterone-induced gene expression. This inhibition leads to cell cycle arrest, primarily by downregulating S phase cyclin A and M phase cyclin B1, both of which are required for cell cycle progression. In cancer models, Mifepristone modulates the PR/p53/HO1/GPX4 signaling network, inducing tumor cell ferroptosis and reducing proliferation (APExBIO B1511). In reproductive biology, Mifepristone inhibits the progesterone-induced acrosome reaction in human sperm, as well as suppressing sperm hyperactivation and reducing intracellular calcium influx in a dose-dependent manner. Its effects on tumor xenografts are attributed to both direct anti-proliferative activity and modulation of local hormone-dependent signaling.

Evidence & Benchmarks

• In vitro, Mifepristone inhibits ovarian, breast, prostate, and gastric adenocarcinoma cell proliferation at concentrations as low as 0.04 μM, with maximal effects observed at 40 μM (APExBIO).
• In animal tumor xenograft models, subcutaneous administration of 0.5–1.0 mg/day Mifepristone significantly reduces tumor size (product data).
• Mifepristone treatment reduces uterine fibroid volume and suppresses meningioma cell proliferation in vivo (protocols and translational insights).
• The compound dose-dependently inhibits progesterone-induced acrosome reaction, sperm hyperactivation, and intracellular calcium concentration in human sperm (reviewed evidence).
• High-purity (>99%) Mifepristone is stable in DMSO and ethanol at ≥21.48 mg/mL, but insoluble in water, with optimal storage at -20°C (specification sheet).

This article extends the mechanistic focus of EpigeneticsDomain by providing actionable protocol parameters and clarifying solubility and storage details critical for reproducible cancer and reproductive biology workflows.

Applications, Limits & Misconceptions

Mifepristone (RU486) is extensively used in both basic and translational research for its dual action in reproductive modulation and oncology. Its capacity to inhibit ovarian cancer cell growth, suppress uterine fibroids, and act as a cell-permeable progesterone receptor antagonist makes it indispensable in hormone-driven disease models. However, users should note boundaries related to specificity and experimental design.

Common Pitfalls or Misconceptions

• Mifepristone is not selective for glucocorticoid or androgen receptors; its primary affinity is for the progesterone receptor.
• It is not suitable as a therapeutic agent for neurological conditions involving cytochrome P450, as its mechanism is unrelated to the glucocorticoid receptor pathway detailed in recent neurotoxicity studies (Nkosi & Maseko, 2025).
• The compound is intended solely for scientific research and not for clinical, diagnostic, or direct medical use (APExBIO policy).
• Long-term storage of Mifepristone solutions at room temperature or above -20°C results in reduced activity due to instability.
• Water is not a recommended solvent due to poor solubility; DMSO or ethanol with gentle warming is preferred.

Workflow Integration & Parameters

Protocol Parameters

• Preparation: Dissolve Mifepristone at ≥21.48 mg/mL in DMSO or ethanol; use gentle warming if necessary.
• Cell culture studies: Apply at 0.04–40 μM final concentration; adjust based on cell type and endpoint.
• Animal xenograft models: Administer 0.5–1.0 mg/day subcutaneously; monitor tumor size bi-weekly.
• Storage: Store solid at -20°C; avoid repeated freeze-thaw; stock solutions are stable at -20°C for several months.
• Reproductive assays: Titrate concentration to observe inhibitory effects on acrosome reaction and sperm activity.

For advanced protocol troubleshooting and real-world scenarios, see this Q&A-driven guide, which addresses cell viability and assay reproducibility using APExBIO’s Mifepristone.

Conclusion & Outlook

Mifepristone (RU486) from APExBIO (SKU B1511) offers a high-purity, well-characterized reagent for dissecting progesterone receptor signaling in cancer and reproductive biology research. Its robust inhibitory profiles against tumor cell proliferation, fibroid growth, and sperm function modulation are supported by peer-reviewed evidence and product documentation. As the field advances, integration of precise protocol parameters and awareness of storage/solubility boundaries will further enhance reproducibility and translational relevance. For a protocol-centric perspective, see our advanced workflow article, which complements the mechanistic insights provided here by focusing on experimental implementation in oncology and fertility models.